Newsroom

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Media Center

Media

Scribe eyes clinic with STX-1150 for hypercholesterolemia

January 21, 2026

BioWorld

Read Now

Press Release

Scribe eyes clinic with STX-1150 for hypercholesterolemia

January 21, 2026

BioWorld

Read Now

Media

Epigenetic silencing therapy to enter first human trials, targeting CVD

January 20, 2026

Longevity.Technology

Read Now

Press Release

Epigenetic silencing therapy to enter first human trials, targeting CVD

January 20, 2026

Longevity.Technology

Read Now

Press Release

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

January 20, 2026

Read Now

Press Release

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

January 20, 2026

Read Now

Media

Scribe Therapeutics plans to test cholesterol-lowering epigenetic editing therapy

January 14, 2026

Endpoints

Read Now

Press Release

Scribe Therapeutics plans to test cholesterol-lowering epigenetic editing therapy

January 14, 2026

Endpoints

Read Now

Press Release

Scribe Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 15, 2025

Read Now

Press Release

Scribe Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 15, 2025

Read Now

Media

CRISPR Slashes ‘Bad Cholesterol’ Levels by 95 Percent in Early Results

November 27, 2025

Singularity Hub

Read Now

Press Release

CRISPR Slashes ‘Bad Cholesterol’ Levels by 95 Percent in Early Results

November 27, 2025

Singularity Hub

Read Now

Media

Scribe Therapeutics Verifies In Vivo CRISPR-Based Cardiometabolic Therapies

November 27, 2024

Inside Precision Medicine

Read Now

Media

The 2024 PharmaVoice 100

October 8, 2024

PharmaVoice

Read Now

Media

Engineering The Future Of Genetic Medicine

September 10, 2024

Progress, Potential, and Possibilities

Read Now

Media

Leadership essentials: “Inspire, motivate, and cultivate”

September 9, 2024

BigThink

Read Now

Media

Small Enzymes, Giant Leaps: CRISPR’s Next-Generation Approach to Genetic Diseases

August 5, 2024

BioSpace

Read Now

Media

Future of Epigenetic Medicine

July 22, 2024

FutureBites

Read Now

Press release

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

September 2, 2026

Read Now

Press release

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 1, 2026

Read Now

Press release

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

July 27, 2026

Read Now

Press release

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

July 23, 2026

Read Now

Press release

Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials

June 18, 2026

Read Now

Press release

Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose

May 28, 2026

Read Now

Publications

Publication

Sequential Proofreading Enhances Specificity and Potency of CRISPR-CasX-based Epigenetic Repressors

August 31, 2026

bioRxiv

Read Now

Publication

Engineered Allosteric Control Enhances Specificity and Potency of CRISPR-CasX-based Epigenetic Repressors

January 14, 2026

bioRxiv

Read Now

Publication

Single particle charge detection mass spectrometry enables molecular characterization of lipid nanoparticles and mRNA packaging

May 18, 2025

Journal of Controlled Release

Read Now

Publication

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publication

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publication

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publication

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publication

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publication

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publication

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publication

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now